Table 3.
Influence of disease conditions on the pharmacodynamics of CNS depressants and CNS stimulants
| CNS depressants | CNS stimulants | |
|---|---|---|
| Renal dysfunction | Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflex [35] Effect of experimental renal dysfunction on the pharmacodynamics of ethanol in rats [36] Effect of experimental renal failure on the pharmacodynamics of zoxazolamine and chlorzoxazone [13] Effect of orally administered activated charcoal on the hypnotic activity of phenobarbital and the neurotoxicity of theophylline administered intravenously to rats with renal failure [109]b |
Effect of experimental renal failure on the pharmacodynamics of theophylline-induced seizures in rats [37] Disparate effects of pentylenetetrazol in rats as a function of renal disease model and pharmacologic endpoint [16] Effect of orally administered activated charcoal on the hypnotic activity of phenobarbital and the neurotoxicity of theophylline administered intravenously to rats with renal failure [109]b |
| Liver disease | Effect of experimental liver diseases on the pharmacodynamics of phenobarbital and ethanol in rats [110] Effect of hepatic cirrhosis on the pharmacodynamics and pharmacokinetics of mivacurium in humans [111]a |
Effect of experimental liver disease on the neurotoxicity of theophylline in rats [112] |
| Diabetes | Effect of experimental diabetes on phenobarbital concentrations in rats at onset of loss of righting reflex [113] | |
| Hypertension | Effect of experimental hypertension on the pharmacodynamics of phenobarbital in rats [114] | |
| Hyperthyroidism | Effect of experimental hyperthyroidism on the hypnotic activity of a benzodiazepine (oxazepam) in rats [12] Effect of experimental thyroid disorders on the pharmacodynamics of phenobarbital, ethanol and pentylenetetrazol [115]b |
Effect of experimental thyroid disorders on the pharmacodynamics of phenobarbital, ethanol and pentylenetetrazol [115]b |
Most titles in this table are shortened titles. Full titles of the published papers include Kinetics of Drug Action in Disease States, followed by a number (I-XLV), and the short title represented in this table
aTitles are the full title of the published paper
bIf both CNS depressants and CNS stimulants are reported in one published paper, the paper is mentioned twice in the table